1. KIMBERLY K. BELL R.N., M.B.A
16993 Station Road Columbia Station, OH 44028
 Phone: (440) 773-2164 or 216-312-9293
5inone17@gmail.com
CAREER PROFILE
Institute/ Service line Administrator: Role conversion Vice President of Operations
Senior Executive with extensive experience in healthcare strategic planning, innovation and operations.
Responsible for $950 million P&L with 800 employees and 115 physicians that has seen 8-10% growth
year over year for 6 years. Top performing business unit achieving financial and business goals within $5.9
billion Corporation through strategic initiatives, market growth, acquisitions and operational efficiencies.
Practice management of integrated health system inclusive of clinic and hospital based service line which
includes Main Campus, 9 Health Centers, 2 standalone Cancer Centers and 7 Hospitals local and national.
QUALIFICATIONS SUMMARY
 Operations experience –$1 billion P&L and service
line budget management, revenue cycle
management, standard operating procedures for
hospital outpatient practice. patient flow, staffing
and productivity models
 Strategic planning for integrated healthcare system
and business units. Business management and
Continuous improvement tools and practices– e.g.
strategic planning, business management practices,
operating plans, scorecards, review forums, frontline
management boards
 Business Growth – Affiliate Program development
and integration, acquisitions and alliances
 Leadership development. Human Resource
Management and Talent Development – hire, train,
develop talent
 Cancer Practice– Hematology, Medical
Oncology, Radiation, Bone Marrow and
Stem Cell Transplant, Palliative Medicine
 Research Operations- clinical and
translational: protocol and budget
management, research grants, pharmaceutical
and philanthropic
 Inpatient- throughput and quality
management, APR-DRG cost management
 Community Outreach Program development
for the underserved. Created hospital and
community based lay navigation program to
treat underserved within Cuyahoga County.
Obtain $300k dollar grant from Harold
Freeman Navigation Center. Continued
support via philanthropic dollars

2. PROFESSIONAL EXPERIENCE
Cleveland Clinic, Cleveland Ohio 1987- Current
The Cleveland Clinic is a not for profit academic medical center with $5.9 billion operating budget. It
provides patient centered care through disease focused institutes, hospitals and community centers.
The Clinic is ranked nationally in the US News and World Reports for the top 10 adult specialties.
The Cancer Institute is ranked #9 in USNWR national survey.
Taussig Cancer Institute, Chief Administrator for Cancer Institute (2010 to Present)
Re-recruited to TCI Administrator role. Report directly to the Chairman of Institute. Responsible for
Administration of Institute and regional oncology services in 9 family health centers and 7 Cleveland
Clinic Health System Hospitals. Scope includes all clinical and business operations, as well as the
Research Department within the institute. Gross clinical revenue totaling $950 mil, $10 million in
Research Funding and $35 million in Philanthropic funds, Revenue and profitability increased 8-10%
year over year for the last 6 years through market growth, acquisitions and operational efficiencies.
Patient volume: 500,000 patient visits- 6500 new cancer case annually; 115 Staff physicians, FTE:
800, 37 bed oncology, 50 bed BMT/Leukemia and 17 bed palliative medicine inpatient units
throughput and quality.
Office of Professional Staff; Administrator, Solon and Chagrin Family Health Centers (FHC)
(2009 – 2010)
Reported to Chief Administrative Officer of the Cleveland Clinic, Co- lead on Health-System service
line cost management committee, managed Clinical Services at family health centers. Introduced
business management practices and visual management structure within the FHCs future
implementation of business review tools..
Medical Operations Division; Senior Director, Strategic Planning & Continuous Improvement
(2008 – 2009)
Reported to Executive Director, SPCI. Responsible for developing 50 person internal consulting group
to provide strategic planning and performance improvement methodologies across enterprise; support
to a $5B Enterprise; achieved $20million dollar impact in 2008 and $31million in 2009.
Taussig Cancer Institute, Chief Administrator for Cancer Institute (2005 – 2009)
Reported directly to the Chairman of Institute. Responsible for Administration of Institute and
regional oncology services in 8 family health centers and 5 Cleveland Clinic Health System Hospitals.
Scope includes all clinical and business operations, as well as the Research Department within the
institute. Responsible for $410 mil gross revenue; grew revenue on average 15% year over year; grew
research 45% actual revenue ; Grew new patient volumes 10% while maintaining physician / staff
ratio 1:2 (excludes research ftes). Managed FTE: 450, Physician staff 80, inpatient; 37 oncology, 16
BMT and 17 palliative medicine inpatient beds focused on quality and throughput needs. During this
time introduced continuous improvement practices, visual management and standard work flows
throughout the Institute. Realigned clinical staffing model and developed management team to support
efficient quality care for our patients. Developed and executed strategic direction for growth , quality,
employees and research. Elevated Cancer Center from #48 in the US News and World Report to #9 in
the rankings.
Taussig Cancer Institute, Chief Administrator for Hematology and Medical Oncology (2004 to
2005)
Reported to Chair of Institute; Responsibility for $110M ($34M Net Rev) $30 million dollars of
philanthropic funds, 200 employees and 25 Staff physicians. Patient visits 84,000, infusion clinic with
70 chairs and 10 bed apheresis unit. Developed leadership team to accept innovation and change to

3. improve practices and operational efficiencies this was precursor to the work we completed at the
institute level. Initiated team building efforts across department leadership, as a result wait time in
chemotherapy infusion center decreased from 1.5 hrs to 25 min which has been sustained for 7 years
through continuous improvement tools. Achieved 40% contribution margin, met access target of
patients seen within 7 days our average 3-5. Standard operating procedures developed for infusion
center, clinical and administrative to improve care delivery system. Recruited by Institute Chairman to
serve in the Institute Administrative role within the year.
Taussig Cancer Institute, Program Administrator, Bone Marrow Transplant and Leukemia
Programs
(1998 to 2004)
Reported to Program Director. Managed $10M in philanthropic funds. Responsible for outpatient bone
marrow transplant program operations and oversight for 17 bed inpatient bone marrow
transplant unit. Managed 10 Staff Physicians. FTE: 30
Administrator, The Ohio Hematopoeitic Stem Cell Consortium (2000 – 2003)
Negotiated service contract between The Cleveland Clinic and the Ohio Stem Cell Consortium.
Developed budget for the operations of the Consortium to be relocated to the Cleveland Clinic.
Coordinated and completed formal reviews for Medicaid approvals for patients receiving bone
marrow transplants.
Autologous Stem Cell Coordinator/Bone Marrow Transplant Research Coordinator, Cleveland
Clinic Foundation (1994-1998)
Coordinate and facilitate the care of a patient undergoing an autologous stem cell transplant. Assess
patient eligibility for stem cell transplantation by collaborating with physicians, nurses, insurance
companies and numerous other disciplines. Coordinate patient care in the outpatient setting. Assist
as a resource person for insurance companies and medical personnel. Direct and assist with
obtaining research protocols related to the field of bone marrow transplantation. Implement and
coordinate clinical trials; co-author on many articles.
Staff Nurse; Bone Marrow Transplant Unit, Cleveland Clinic Foundation (1991 – 1994)
Responsible for direct patient care of bone marrow transplant patients. Plan, assess, implement and
evaluate a plan of care for hospitalized patients. Preceptor for new staff nurses. Quality assurance
monitor.
Staff Nurse; Colorectal Surgical Unit, Cleveland Clinic Foundation (1987 – 1991)
Responsible for direct patient care for postoperative patients with colorectal cancers, Crohn’s disease,
ulcerative colitis and other related complications. Preceptor for new staff nurses. Quality assurance
monitor. Charge nurse duties including coordination of staffing and scheduling.
EDUCATION & CREDENTIALS
Degrees
Master in Business and Healthcare Administration,
Cleveland State University
2000-2005
Bachelor of Science in Nursing,

4. Kent State University
1984-1987
Nursing
PROJECTS AND COMMITTEES
Co-lead for Enterprise Service-line Cost Management Committee 2008-2010
Co-Lead Enterprise Revenue Cycle Management 2012-current
Enterprise ICD-10 Committee 2013-current
Case Comprehensive Cancer Center member 2012-current
Community Advisory Board- Case Comprehensive Cancer Center; serve the community in developing
service needs for the underserved population 2012-current
Board Member North East Ohio MedWorks (Not-for Profit Group for underserved population) 2012-
current
Member ACHE 2009-current

5. PUBLICATIONS / CLINICAL
TRIALS
Immunex Corporation A randomized study of GM-CSF versus G-CSF in stem cell
priming in autologous bone marrow transplantation.
Sandoz Corporation Randomized trail of G-CSF with/without IL3 for autologous
progenitor cell transplantation.
Amgen, Inc. A randomized, placebo, blinded, phase I/II trial of pegylated
recombinant human megakaryocyte growth factor.
Ortho-Biotech Randomized trial for Procrit post autologous stem cell transplant.
ABSTRACTS
1. BOLWELL B, ANDRESEN S, KALAYCIO M, DANNLEY R, SERAFIN M, WISE K, et
al. Platelet Transfusion Requirements during Autologous Progenitor Cell Transplantation
(ABMT) Correlate with the Pretransplant Platelet Count. Proc ASH 1996, vol. 88 (suppl 1):
122a (abstract #477)
2. BOLWELL B, OVERMOYER B, KALAYCIO M, GOORMASTIC M, ANDRESEN S,
DANNLEY R, WISE K, et al. Factors Associated with Delayed G-CSF Primed PBPC
Collection. ASH 1997.
3. BOLWELL B, POHLMAN B, OVERMOYER B, ANDRESEN S, GOORMASTIC M,
DANNLEY R, SERAFIN M, LICHTIN A, WISE K and KALAYCIO M. The G-CSF
Primed WBC Correlates with CD34+ Cell Yield. ASH 1997.
4. BOLWELL B, CAPOZZI D, POHLMAN B, OVERMOYER B, ANDRESEN S,
GOORMASTIC M, DANNLEY R, WISE K, et al. A Prospective Randomized Clinical and
Economic Trial of Sequential GM-CSF/G-CSF versus G-CSF for Peripheral Blood
Progenitor Cell (PBPC) Mobilization. Cleveland Clinic Foundation, 1998.

6. 5. BOLWELL B, ANDRESEN S, KALAYCIO M, GOORMASTIC M, DEMARS D, WISE
K, et al. Kinetics of Etoposide (VP –16) Plus G-CSF Peripheral Blood Progenitor Cell
(PBPC) Mobilization. ASH Abstract, 1999.
6. POHLMAN B, SUTKOWI L, KALAYCIO M, ANDRESEN S, SOBECKS R, WISE K, et
al. Autologous Peripheral Blood Progenitor Cell (PBPC) Transplantation for Transformed
Non-Hodgkin’s Lymphoma. Proc ASCO 2000, 19:54a (abstract #209).
7. BOLWELL B J, ANDRESEN S W, POHLMAN B L, SOBECKS R M, GOORMASTIC
M, DEMARS D D, WISE K K, et al. The Prognostic Importance of the Axillary Lymph
Node Ratio in Autologous Transplantation for High Risk Stage II – III Breast Cancer. Proc
ASCO 2000, 19:57a (abstract #219).
8. B, KALAYCIO M, ANDRESEN S, GOORMASTIC M, MCBEE M, KUCZKOWSKI E,
BERNHARD L, KRIVOY M, SOMMER H, WISE K, et al. Bone Marrow Involvement in
Patients with Diffuse Large Cell Lymphoma (DLCL) Undergoing Autologous Stem Cell
Transplantation. ASH 2000.
9. BOLWELL B, KALAYCIO M, SOBECKS R, ANDRESEN S, GOORMASTIC M,
LONGWORTH D, AVERY R, MOSSAD S, KUCZKOWSKI EK, BERNHARD L,
SOMMER H, WISE K, and POHLMAN B. The Efficacy of Prophylactic Outpatient
Antibiotics for the Prevention of Neutropenic Fever Associated with high Dose VP-16 for
Stem Cell Mobilization. ASH 2000.
10. BOLWELL B, KALAYCIO M, SOBECKS R, ANDRESEN S, WISE K, MCBEE M, et al.
Peripheral Blood Progenitor Cell Mobilization: VP-16 + G-CSF Generates Fewer
CD34+CD33- Cells than G-CSF Alone. ASH 2000.
11. BOLWELL B, POHLMAN B, ANDRESEN S, WISE K, CURTIS J, et al. Rapid
Development of Full Chimerism after Non-myeloablative Allogeneic BMT using a
Preparative Regimen of Fludarabine and Low Dose TBI. ASH 2000.
12. Bolwell B, Sobecks R, Pohlman B, Andresen S, Bell K, Bernhard L, Koenecke J, Serafino S,
Ostendorf H, Theil K, Kuczkowski L, Rybicki L, Jarvis J, & Kalaycio M. Etoposide (VP 16)
+ G-CSF Mobilizes Different Dendritic Cell Subsets Than Does G-CSF Alone. Bone
Marrow Transplantation, The Cleveland Clinic Foundation, Cleveland, Ohio 2001.
13. Bolwell B, Sobecks R, Pohlman B, Andresen S, Bell K, Bernhard L, Koenecke J, Serafino S,
Ostendorf H, Theil K, Kuczkowski L, Rybicki L, Jarvis J, & Kalaycio
M.Hypogammaglobinemia Following Non-Myeloablative Allogeneic Stem Cell Transplant
Correlates With Chimerism. Bone Marrow Transplantation, The Cleveland Clinic
Foundation, Cleveland, Ohio 2001.
ARTICLES

7. 1. BOLWELL B, GOORMASTIC M, DANNLEY R, ANDRESEN S, OVERMOYER B,
MENDEZ Z, KALAYCIOGLU M, DEMARS D, WISE K and POHLMAN B. G-CSF
Post-autologous Progenitor Cell Transplant: A Randomized Study of 5, 10 and 16
mcg/kg/day. In press 1997.
2. ABDEL-RAZEQ H, POHLMAN B, ANDRESEN S, OVERMOYER B, WISE K, et al. A
Randomized Study of Multi-day Infusion of Autologous Peripheral Blood Progenitor Cells.
Bone Marrow Transplantation 1998, 21:221-223.
3. BOLWELL BJ, POHLMAN B, ANDRESEN S, KALAYCIO M, GOORMASTIC M,
WISE K, et al. Delayed G-CSF after Autologous Progenitor Cell Transplant: A Prospective
Randomized Trial. Bone Marrow Transplantation 1998, 21:369-373.
4. BOLWELL B, GOORMASTIC M, ANDRESEN S, KOO A, WISE K, OVERMOYER B,
et al. Variable Associated with the Platelet Count Six Weeks after Autologous Peripheral
Cell Transplantation. In press 1998.
5. BOLWELL B, POHLMAN B, KALAYCIO M, WISE K, GOORMASTIC M and
ANDRESEN S. LDH elevation after autologous stem cell transplantation. Bone Marrow
Transplantation 1999, 24:53-55.
6. BOLWELL B, KALAYCIO M, ANDRESEN S, GOORMASTIC M, MCBEE M,
KUCZKOWSKI E, WISE K, et al. Autologous Peripheral Blood Progenitor Cell
Transplantation for Transformed Diffuse Large-Cell Lymphoma. Clinical Lymphoma 2000,
1:226-231.
7. Bolwell B, Andresen S, Sobecks R, Goormastic M, Rybicki, Bell K, and Kalaycio M.
Prognostic Importance of the Axillary Lymph Node Ratio in Autologous Transplantation
for High-Risk II/III Breast Cancer. Bone Marrow Transplantation (2001) 27, 843-846.
8. Bolwell B, Sobecks R, Pohlman B, Andresen S, Lichtin A, Rybicki L, Kuczkowski L, west A,
Bell, K, Shamp J, Serafin M, Kosar J, Sands K, Kalayion M. A Prospective Randomized
Trial Comparing Cyclosporine +Short Course Methotrexate To Cyclosporine +
Mucophenolate For GVHD Prophylaxis In Ablative Allogeneic BMT
9. Bolwell B, Andresen S, Kalaycio M, Sobecks R, Rybicki L, Kuczowski E, Brown S, Shamp J,
Bell K, Curtis J, Pohlman B. Predictive Factors of Survival Following Autologous Stem Cell
Transplant(ABMT) For Follicular NHL
PROTOCOLS
1. A Prospective Randomized Trial of G-CSF 10 mcg/kg/d versus G-CSF 30 mcg/kg/d for
the Mobilization of Peripheral Blood Progenitor Cells (PBPC). IRB #2409
2. An Open-Label, Multi-Center, Dose-Finding Phase I/II Study of the Safety and Biological
Activity of Allomune Component II: Medi-507 as part of a Non-Myeloablative

8. Conditioning Regimen for Allogeneic Stem Cell Transplantation in the Treatment of
Patients with Refractory Non-Hodgkin’s Lymphoma or Hodgkin’s Disease. IRB #3436
3. A Phase II/III Multi-Center, Open-Label, Randomized Clinical Trial Evaluating ABX-CBL
when compared to ATGAM as Second Line Therapy in Patients with Steroid Resistant
AGVHD. IRB #3393 ABX-CB-9906
4. ABX-CBL Blood Study Protocol to Monitor the Expression of CD147 Antigen on Various
Cell Populations at Various Timepoints after Allogeneic Stem Cell Transplantation. IRB
#3576 ABX-CBL-NC-001
5. A Multi-National, Multi-Center, Double-Blind, Placebo-Controlled Randomized, Phase III
Clinical Trial to Determine the Efficacy and Safety of IB-367 Rinse in Reducing the Severity
of Oral Mucositis in Patients Receiving Stomatotoxic Chemotherapy. IRB #3731
6. Long-Term Follow-Up Study for Patients Treated under Protocol BTI-0301, ‘An Open-
Label, Multi-Center, Dose-Finding Phase I/II Study of the Safety and Biological Activity of
Allomune Component II: Medi-507 as part of a Non-Myeloablative Conditioning Regimen
for Allogeneic Stem Cell Transplantation in the Treatment of Patients with Refractory Non-
Hodgkin’s Lymphoma or Hodgkin’s Disease. IRB #3799
7. A Prospective Randomized trial of Cyclosporine Plus Methotrexate versus Cyclosporine Plus
Mycophenolate for the Prevention of Acute Graft Versus Host Disease in Patients Receiving
a High-Dose Chemotherapy Preparative Regimen of Busulfan and Cyclophosphamide. IRB
#4117